HER2-Negative Breast Cancer Market Report 2026

The her2-negative breast cancer market size has grown strongly in recent years. It will grow from $17.57 billion in 2025 to $18.95 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing breast cancer screening rates, rising awareness of hormone receptor-positive cancers, expansion of oncology treatment centers, availability of established chemotherapy protocols, growth in clinical oncology research.

The her2-negative breast cancer market size is expected to see strong growth in the next few years. It will grow to $25.41 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing demand for personalized oncology treatments, rising adoption of genomic-driven therapies, expansion of immunotherapy pipelines, growing focus on improving progression-free survival, increasing investment in oncology drug development. Major trends in the forecast period include increasing adoption of personalized hormone therapy regimens, growing use of cdk4/6 inhibitors, expansion of genomic testing for treatment selection, rising integration of immunotherapy in advanced stages, enhanced focus on combination treatment protocols.

The rising incidence of breast cancer is expected to drive the growth of the HER2-negative breast cancer market in the coming years. Breast cancer is characterized by the uncontrolled growth of abnormal cells in breast tissue, typically originating in the ducts or lobules. The increasing number of breast cancer cases is influenced by factors such as heightened awareness and improved screening methods, leading to earlier and more frequent detection. HER2-negative breast cancer plays a key role in advancing research by providing insights into distinct tumor biology and treatment strategies, facilitating the development of more targeted therapies. For example, according to the American Cancer Society, the United States is projected to see approximately 316,950 new cases of invasive breast cancer in women and 2,800 cases in men in 2025, along with an estimated 59,080 cases of ductal carcinoma in situ (DCIS) diagnosed in women. Therefore, the rising incidence of breast cancer is driving the HER2-negative breast cancer market.

Key companies in the HER2-negative breast cancer market are focusing on obtaining regulatory approvals to introduce new treatments, expand their product portfolios, and strengthen their market presence. Regulatory approvals are official authorizations granted by government agencies that allow companies to market and distribute drugs after meeting safety, efficacy, and quality standards. For instance, in October 2024, Genentech Inc., a US-based biotechnology company, received FDA approval for Itovebi (inavolisib) as a targeted therapy for advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This approval permits the use of Itovebi in combination with palbociclib and fulvestrant, significantly improving progression-free survival compared to standard treatments. The regimen provides an important option for patients with limited alternatives, highlighting the value of biomarker testing to identify those most likely to benefit.

In June 2024, Relay Therapeutics Inc., a US-based clinical-stage precision medicine company, collaborated with Pfizer Inc. to evaluate atirimociclib, Pfizer’s investigational selective CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2-negative metastatic breast cancer. The collaboration also seeks to leverage the unique properties of both drugs to minimize off-target toxicity, which has previously limited the efficacy of non-selective agents. Pfizer Inc., a US-based pharmaceutical and biotechnology company, is actively involved in developing treatments for HER2-negative breast cancer.

Major companies operating in the her2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

North America was the largest region in the HER2-negative breast cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the her2-negative breast cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the her2-negative breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the her2-negative breast cancer market by increasing costs of imported oncology drugs, biologics, diagnostic kits, and laboratory reagents used across chemotherapy, hormone therapy, and targeted treatment regimens. Oncology centers in North America and Europe are most affected due to dependence on imported pharmaceuticals, while Asia-Pacific faces cost pressure on advanced diagnostic imports. These tariffs are contributing to higher treatment expenses and reimbursement challenges. However, they are also encouraging domestic drug manufacturing, regional clinical trial expansion, and local production of oncology therapeutics.

The her2-negative breast cancer market research report is one of a series of new reports that provides her2-negative breast cancer market statistics, including her2-negative breast cancer industry global market size, regional shares, competitors with a her2-negative breast cancer market share, detailed her2-negative breast cancer market segments, market trends and opportunities, and any further data you may need to thrive in the her2-negative breast cancer industry. This her2-negative breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

HER2-negative breast cancer is a type of breast cancer in which cancer cells do not overexpress the HER2 protein, a factor that promotes tumor growth. This form of cancer generally grows more slowly than HER2-positive breast cancer and is treated with targeted therapies, chemotherapy, and other treatment options.

The main treatment approaches for HER2-negative breast cancer include chemotherapy, hormone therapy, targeted therapy, and immunotherapy. Chemotherapy involves the use of potent drugs to kill or inhibit the growth of cancer cells by targeting rapidly dividing cells in the body. Treatment is tailored to different stages of the disease, including early-stage, locally advanced, and metastatic breast cancer. Chemotherapy and other related therapies are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The HER2-negative breast cancer market includes revenues earned by entities by providing services such as radiation therapy, genetic testing, mammography, and counseling and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.